M&A Deal Summary

Valerio Therapeutics Acquires DNA Therapeutics SA

On February 29, 2016, Valerio Therapeutics acquired life science company DNA Therapeutics SA for 2M EUR

Acquisition Highlights
  • This is Valerio Therapeutics’ 1st transaction in the Life Science sector.
  • This is Valerio Therapeutics’ largest (disclosed) transaction.
  • This is Valerio Therapeutics’ 1st transaction in France.

M&A Deal Summary
Date 2016-02-29
Target DNA Therapeutics SA
Sector Life Science
Buyer(s) Valerio Therapeutics
Deal Type Add-on Acquisition
Deal Value 2M EUR

Target

DNA Therapeutics SA

Evry, France
DNA Therapeutics SA is a clinical-stage biopharmaceutical company, for its signal-interfering DNA (siDNA) repair technology, which is directed at overcoming cancer resistance mechanisms, and includes lead product candidate DT01.

Search 198,242 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Valerio Therapeutics

Paris, France
Category Company
Founded 1997
Sector Life Science
Employees29
Revenue 2M EUR (2023)
DESCRIPTION

Valerio Therapeutics is a clinical-stage biotechnology company developing innovative oncology drugs targeting tumor DNA-binding functions through unique mechanisms of action in the sought-after field of DNA Damage Response (DDR). The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners. Valerio Therapeutics was founded in 1997 and is based in Paris, France.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
Country (France) 1 of 1
Year (2016) 1 of 1
Size (of disclosed) 1 of 1
Mergr

Product

Company

Legal